Bank of America Securities is cautioning that the recent momentum in US biotech stocks is fading, as investors find fewer near-term events to drive share prices. The firm notes that several well-known names—BridgeBio Pharma, Madrigal Pharmaceuticals, and Cytokinetics—have slid in recent weeks, while Ligand Pharmaceuticals has bucked the trend as this year's rare outperformer.
What's driving the pullback?
Biotech shares are notoriously event-driven. Unlike many other sectors, where earnings and broad economic data move the tape, biotech valuations often hinge on a pipeline of specific milestones: clinical-trial readouts, regulatory approval decisions, or early sales figures for newly launched drugs. When that calendar is full, investors are willing to pay up for the potential upside of a positive result. When it goes quiet, the calculus shifts.
According to BofA, that's exactly what's happening now. With fewer high-profile catalysts on the immediate horizon, investors are less inclined to pay for "what could happen next" and more focused on "what's likely to happen before the next big update." That means paying closer attention to the less glamorous fundamentals: ongoing losses, cash burn, and how long a company's existing capital will last before it needs to raise more.
This dynamic is common in the biotech space, where many companies are years away from profitability and depend on regular infusions of investor capital to fund research and development. When sentiment turns cautious, stocks that trade heavily on future promise can be hit hardest.
Who's been hit, and who's holding up?
The three decliners named by BofA are all mid-to-large cap biotechs with significant pipelines. BridgeBio Pharma has been focused on rare genetic diseases, including a high-profile drug for a heart condition. Madrigal Pharmaceuticals recently won approval for a liver disease treatment and is working on commercial launch. Cytokinetics is developing treatments for heart conditions and has been a frequent subject of M&A speculation.
All three have seen their shares slide in recent weeks, reflecting the broader loss of momentum. In contrast, Ligand Pharmaceuticals has been a standout. Ligand operates a different business model—it licenses out its drug technology and collects royalties and milestones from partners, rather than bearing the full cost of drug development itself. That model tends to produce more predictable revenue, which may be why investors are treating it as a safer haven in a choppy environment.
What it means for everyday investors
For ordinary investors, the key takeaway is that biotech is a high-risk, high-reward corner of the market, and timing matters. When the catalyst calendar is full, stocks can surge on a single positive trial result. But when that calendar thins out, the same stocks can drift or fall as investors refocus on cash burn and the long road to profitability.
This is not a reason to avoid biotech altogether, but it underscores the importance of understanding what you own. If you hold a biotech stock or a biotech-focused exchange-traded fund, it's worth checking what major data readouts or regulatory decisions are scheduled in the coming months. A quiet period can be just as important as a busy one.
For context, the broader biotech sector has been volatile this year. A recent biotech ETF slide highlighted how setbacks at individual companies can drag down the whole group. And while some investors have been rotating into other sectors, the appetite for riskier growth areas like biotech can shift quickly with the macro backdrop.
What to watch next
Investors will be watching for the next wave of clinical data and regulatory decisions to see if the catalyst calendar fills back up. Company earnings calls, which often include pipeline updates, could also provide fresh fuel. In the meantime, BofA's caution suggests that the easy gains in biotech may be over for now, and that selectivity is key.
For those looking at the broader market, the same theme of waiting for catalysts is playing out in other areas. As mega-cap earnings and Treasury yields dominate the week, investors are also weighing how much of the recent rally is built on solid fundamentals versus hope for future events.
Ultimately, the biotech pullback is a reminder that in markets, what you don't know can hurt you—but what you do know, like the timing of the next catalyst, can help you make more informed decisions.
